case_images: PMC7568629_01
case_images: PMC7568629_02
case_images: PMC7568629_03
case_images: Representative magnetic resonance imaging data in the late arterial phase showing the clinical course of the patient. (A) Before systemic therapy the patient had BCLC Stage B/C HCC characterized by multiple disseminated metastases in the left and right lobes of the liver and possible macrovascular invasion (indicated by red arrows); (B) after 2 months of lenvatinib treatment the patient achieved a partial remission (mRECIST criteria); (C) after one month of glucocorticoid therapy and switching from lenvatinib to apatinib the patient experienced progressive disease as evaluated by imaging examination (recurrent disease indicated by red arrows); (D) after switching back to lenvatinib the patient achieved a partial response, with tumor stage recovered to BCLC Stage A.
case_images: OTT-13-10267-g0001.jpg
case_images: PMC7568629_04_OTT-13-10267-g0001.jpg
case_images: f0001
case_images: After one month of lenvatinib treatment, the patient was found to have again achieved a partial response (Figure 1D).
case_images: PMC7568629_04
case_images: Representative magnetic resonance imaging data in the late arterial phase showing the clinical course of the patient. (A) Before systemic therapy the patient had BCLC Stage B/C HCC characterized by multiple disseminated metastases in the left and right lobes of the liver and possible macrovascular invasion (indicated by red arrows); (B) after 2 months of lenvatinib treatment the patient achieved a partial remission (mRECIST criteria); (C) after one month of glucocorticoid therapy and switching from lenvatinib to apatinib the patient experienced progressive disease as evaluated by imaging examination (recurrent disease indicated by red arrows); (D) after switching back to lenvatinib the patient achieved a partial response, with tumor stage recovered to BCLC Stage A.
case_images: OTT-13-10267-g0001.jpg
case_images: PMC7568629_04_OTT-13-10267-g0001.jpg
case_images: f0001
case_images: After one month of lenvatinib treatment, the patient was found to have again achieved a partial response (Figure 1D).
case_images: Representative PET-CT imaging showing bone and lung metastasis.
case_images: OTT-13-10267-g0002.jpg
case_images: PMC7568629_04_OTT-13-10267-g0002.jpg
case_images: f0002
case_images: The patient was followed up for the last time on April 21, 2020, and PET-CT revealed bone and lung metastasis (Figure 2).